Skip to main
LRMR

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics has demonstrated a significant increase in median frataxin (FXN) expression, rising from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, markedly exceeding the performance seen in healthy volunteers. Additionally, the company's lead product candidate shows a median improvement of -2.20 points in the modified Friedreich’s Ataxia Rating Scale (mFARS), contrasting favorably with a decline of +1.00 points observed in the FACOMS natural history population over the same period. These compelling efficacy data highlight the potential of Larimar's innovative CPP technology to provide meaningful therapeutic benefits for patients with Friedreich's ataxia, supporting a positive outlook for the company's stock performance.

Bears say

Larimar Therapeutics Inc. is facing a negative outlook due to its significant revision of future revenue estimates, with projections for FY29 decreasing from $659 million to $407 million, indicating potential challenges in achieving market penetration within the Friedreich's ataxia (FA) market. The company's lead product candidate, CTI-1601, shows concerning clinical trial results, notably a median mFARS change of -2.20 points, which contrasts with a +1.00 point decline in the FACOMS natural history population, raising questions about its efficacy. Additionally, the expected market share of approximately 25% may not be sufficient to sustain confidence in the company's growth trajectory given these data points.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.